Coviran Barkat ® an approved vaccine against COVID-19 virus

Coviran Barkat ® as an approved vaccine by Iran Food and Drug Administration (IFDA) against COVID-19 virus

Coviran Barkat ® Produced vaccine by Shifa Pharmed Industries Group, is based on inactivated Covid-19 virus (killed).

Production process perform in a sterile environment and proliferate under Level 3 of Biosafety conditions, inactivated by suitable substance, purified on special chromatographic column, formulated, and finally prepared as 0.5 ml suspension in sterile vials for intramuscular injection use.

Following the approval of physicochemical tests, safety and immunogenicity studies in animal models, the Covid-19 vaccine is currently undergoing clinical trials in humans under the supervision of the Ministry of Health, the Iran Food and Drug Administration (IFDA), and the National Ethics Committee. Filled vials should be stored at 2 to 8 ° C without freezing.

Coviran Barkat ® as an approved vaccine by Iran Food and Drug Administration (IFDA) against COVID-19 virus, contains 5μg inactivated purified virus as the immunogenic antigen

per each dose. In manufacturing process of Coviran Barkat ® vaccine, the virus is propagated in Vero cells followed by inactivation, purification and finally, formulation with aluminium hydroxide as adjuvant. Coviran Barkat ® vaccine is provided in both single and multi-dose (10 doses) vials. This vaccine is manufactured and tested according to World Health Organization (WHO) requirements. The vaccine stimulates the immune system to induce antibodies as well as cellular immunity response against the SARS COV-2, as causative agent of Covid-19 infection.

 

The summary  is avialable here.